Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid.  The research was conducted in collaboration with academic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège as well as with the Université de Neuchâtel, Switzerland.

The Company’s lead programme, Ir-CPI, is the first in a novel class of antithrombotics, and is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. Thanks to a novel mechanism of action, Ir-CPI is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures.

Bioxodes owns issued and pending patents relating to Ir-CPI.

 

Latest News

Bioxodes’ antithrombotic meets development milestones - Company to launch Series A investment round to bring product to the clinic

Marche-en-Famenne, Belgium – Bioxodes SA, the Belgian-based start-up developing pharmaceutical products ...
Read more